Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 19, 2006, Pages 5107-5111

  Tully, David C ^a   Liu, Hong ^a   Chatterjee, Arnab K ^a   Alper, Phil B ^a   Williams, Jennifer A ^a   Roberts, Michael J ^a   Mutnick, Daniel ^a   Woodmansee, David H ^a   Hollenbeck, Thomas ^a   Gordon, Perry ^a   Chang, Jonathan ^a   Tuntland, Tove ^a   Tumanut, Christine ^a   Li, Jun ^a   Harris, Jennifer L ^a   Karanewsky, Donald S ^a  

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

Cathepsin; Cysteine protease inhibitor; Non covalent inhibitor; Peptidomimetic

Indexed keywords

CARBAMIC ACID DERIVATIVE; CATHEPSIN S; CATHEPSIN S INHIBITOR; CYSTEINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CARBAMATES; CATHEPSINS; HUMANS; MALE; MOLECULAR MIMICRY; OLIGOPEPTIDES; PROTEASE INHIBITORS; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33747354109     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.07.032     Document Type: Article

References (22)

1. Riese R.J., Mitchell R.N., Villadangos J.A., Shi G.P., Palmer J.T., Karp E.R., De Sanctis G.T., Ploegh H.L., and Chapman H.A. J. Clin. Invest. 101 (1998) 2351
2. Villandangos J.A., Bryant R.A.R., Deussing J., Driessen C., Lennon-Duménil A.-M., Riese R.J., Roth W., Saftig P., Shi G.P., Chapman H.A., Peters C., and Ploegh H.L. Immunol. Rev. 172 (1999) 109
3. Shi G.P., Villandangos J.A., Dranoff F., Small C., Gu L., Haley K.J., Riese R., Ploegh H.L., and Chapman H.A. Immunity 10 (1999) 197
4. Nakagawa T.Y., and Rudensky A.Y. Immunol. Rev. 172 (1999) 121
5. Honey K., and Rudensky A.Y. Nat. Immunol. 3 (2003) 472
6. Beers C., Burich A., Kleijmeer M.J., Griffith J.M., Wong P., and Rudensky A.Y. J. Immunol. 174 (2005) 1205
7. Riese R.J., Wolf P.R., Brömme D., Natkin L.R., Villadangos J.A., Ploegh H.L., and Chapman H.A. Immunity 4 (1996) 357
8. Driessen C., Bryant R.A.R., Lennon-Duménil A.-M., Villadangos J.A., Bryant P.W., Shi G.-P., Chapman H.A., and Ploegh H.L. J. Cell Biol. 147 (1999) 775
9. Thurmond R.L., Sun S., Karlsson L., and Edwards J.P. Curr. Opin. Invest. Drugs 6 (2005) 473
10. Leroy V., and Thurairatnam S. Expert Opin. Ther. Patents 14 (2004) 301
11. Yang H., Kala M., Scott B.G., Goluszko E., Chapman H.A., and Christadoss P. J. Immunol. 174 (2005) 1729
12. Nakagawa T.Y., Brissette W.H., Lira P.D., Griffiths R.J., Petrushova N., Stock J., McNeish J.D., Eastman S.E., Howard E.D., Clarke S.R.M., Rosloniec E.F., Elliott E.A., and Rudensky A.Y. Immunity 10 (1999) 207
13. Liu H., Tully D.C., Epple R., Bursulaya B., Li J., Harris J.L., Williams J.A., Russo R., Tumanut C., Roberts M.J., Alper P.B., He Y., and Karanewsky D.S. Bioorg. Med. Chem. Lett. 15 (2005) 4979
14. Alper P.B., Liu H., Chatterjee A.K., Nguyen K.T., Tully D.C., Tumanut C., Li J., Harris J.L., Tuntland T., Chang J., Gordon P., Hollenbeck T., and Karanewsky D.S. Bioorg. Med. Chem. Lett. 16 (2006) 1486
15. Tully D.C., Liu H., Alper P.B., Chatterjee A.K., Epple R., Roberts M.J., Williams J.A., Nguyen K.T., Woodmansee D.H., Tumanut C., Li J., Spraggon G., Harris J.L., Chang J., Tuntland T., and Karanewsky D.S. Bioorg. Med. Chem. Lett. 16 (2006) 1975
16. Tully, D. C.; Liu, H.; Chatterjee, A. K.; Alper, P. B.; Epple, R.; Williams, J. A.; Roberts, M. J.; Woodmansee, D. H.; Masick, B. T.; Tumanut, C.; Li, J.; Spraggon, G.; Hornsby, M.; Chang, J.; Tuntland, T.; Hollenbeck, T.; Gordon, P.; Harris, J. L.; Karanewsky, D. S. Bioorg. Med. Chem. Lett. preceding paper.
17. Pauly T.A., Sulea T., Ammirati M., Sivaraman J., Danley D.E., Griffor M.C., Kamath A.V., Wang I.K., Laird E.R., Seddon A.P., Menard R., Cygler M., and Rath V.L. Biochemistry 42 (2003) 3203
18. Ward Y.D., Thomson D.S., Frye L.L., Cywin C.L., Morwick T., Emmanuel M.J., Zindell R., McNeil D., Bekkali Y., Giradot M., Hrapchak M., DeTuri M., Crane K., White D., Pav S., Wang Y., Hao M.-H., Grygon C.A., Labadia M.E., Freeman D.M., Davidson W., Hopkins J.L., Brown M.L., and Spero D.M. J. Med. Chem. 45 (2002) 5471
19. Mcgrath M.E., Palmer J.T., Bromme D., and Somoza J.R. Protein Sci. 7 (1998) 1294
20. Synthesis of compound 2: (a) 4a, 7b, HATU, DIEA, DCM, 57%; (b) 4-morpholinecarbonyl chloride, NaH, DMF, rt, 42%.
21. Experimental details of the enzymatic assays and the dilution-dialysis experiment with compound 18 are included in the Supplementary material.
22. 2, EtOH, reflux, 90%; (c) NaH, 1,2-dibromoethane, DMF, 0 °C, 61%; (d) TFA, 60 °C, 75%; (e) LAH, 0 °C, 60%.